Practical outcome of adjuvant folfox4 chemotherapy in elderly patients with stage iii colon cancer: Single-center study in korea

Japanese Journal of Clinical Oncology

Volumn 43, Issue 2, 2013, Pages 132-138

  Kim, Ji Yeon ^a   Kim, Yu Jung ^a   Lee, Keun Wook ^a   Lee, Jong Seok ^a   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Lee, Hye Seung ^a   Jang, Na Young ^a   Kim, Jae Sung ^a   Kim, Jee Hyun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Adjuvant; Aged; Chemotherapy; Colon cancer; FOLFOX4 protocol

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; COLON CANCER; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INFECTION; KOREA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; RECTUM CANCER; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; VOMITING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873492390     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys195     Document Type: Article

References (20)

1. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute 2010;7.
2. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
4. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.
5. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7.
6. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. J Am Med Assoc 2005;294:2703-11.
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
8. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.
9. Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in .12500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 2009;27(Suppl.):15s. (abstr 4010).
10. Greene FL. American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. New York: Springer 2002.
11. National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute 2009.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
13. Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004;8:1061-7.
14. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005;16:1795-800.
15. Lee PH, Park YS, Ji JF, et al. Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: the MASCOT study. Asia-Pacific J Clin Oncol 2009;5:101-10.
16. Sugihara K, Ohtsu A, Shimada Y, et al. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer 2012;11:127-37.
17. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. J Am Med Assoc 2010;303:1037-45.
18. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696- 704.
19. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012;23:1190-7.
20. Chang HJ, Lee KW, Kim JH, et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol 2012;23:911-8.